Shandong Weigao Group Medical Polymer Co (Shandong Weigao Group Medical Polymer Co) COGS-to-Revenue : 0.51 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Shandong Weigao Group Medical Polymer Co COGS-to-Revenue?

Shandong Weigao Group Medical Polymer Co's Cost of Goods Sold for the six months ended in Dec. 2023 was $453 Mil. Its Revenue for the six months ended in Dec. 2023 was $887 Mil.

Shandong Weigao Group Medical Polymer Co's COGS to Revenue for the six months ended in Dec. 2023 was 0.51.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Shandong Weigao Group Medical Polymer Co's Gross Margin % for the six months ended in Dec. 2023 was 48.95%.

Shandong Weigao Group Medical Polymer Co COGS-to-Revenue Historical Data

The historical data trend for Shandong Weigao Group Medical Polymer Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Weigao Group Medical Polymer Co COGS-to-Revenue Chart

Shandong Weigao Group Medical Polymer Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.37

0.44

0.47

0.50

Shandong Weigao Group Medical Polymer Co Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.46	0.48	0.46	0.49	0.51

Shandong Weigao Group Medical Polymer Co COGS-to-Revenue Calculation

Shandong Weigao Group Medical Polymer Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	922.442	/	1852.813
	=	0.50

Shandong Weigao Group Medical Polymer Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	452.676	/	886.775
	=	0.51

Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Shandong Weigao Group Medical Polymer Co's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	452.676 / 886.775
	=	48.95 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Shandong Weigao Group Medical Polymer Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shandong Weigao Group Medical Polymer Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Weigao Group Medical Polymer Co (Shandong Weigao Group Medical Polymer Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shandong Weigao Group Medical Polymer Co Ltd (OTCPK:SHWGF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

SHWGY:USA 01066:Hong Kong UK2:Germany

Address

No.1, Weigao Road, Torch Hi-tech Science Park, Shandong Province, Weihai, CHN

Website

https://www.weigaogroup.com

Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.

Shandong Weigao Group Medical Polymer Co (Shandong Weigao Group Medical Polymer Co) Headlines

From GuruFocus

Shandong Weigao Group Medical Polymer Co Ltd's Dividend Analysis

By GuruFocus Research • 10-26-2023

ACell Enters Exclusive Chinese Product Supply and Distribution Agreement for Cytal and MicroMatrix Wound Management Products

By PRNewswire PRNewswire • 04-08-2019